Chronic rhinosinusitis (CRS) is a debilitating inflammatory disorder of the sinonasal mucosa that substantially diminishes patient quality of life. Progress surrounding management of this disease has been crippled by a lack of therapeutic innovation. It has been posited that increased vascularity within the diseased sinuses of patients with CRS may allow for improved systemic drug delivery via nanoscale liposomal carriers. Such a system could enhance drug distribution, accumulation, and retention within the sinuses, ultimately leading to improved patient outcomes. PEGylated liposomes loaded with indocyanine green (ICG) were synthesized, characterized and systemically administered in a mouse model of CRS. Accumulation and retention of ICG in sinonasal tissue were evaluated. Compared to healthy controls, CRS mice showed significant sinonasal tissue accumulation and retention of PEGylated liposomal ICG for up to 21 days (P < 0.001). Conversely, free ICG was eliminated from the body after 24 h in both groups.

慢性鼻窦炎 (CRS) 是一种使鼻窦粘膜衰弱的炎症性疾病，会严重降低患者的生活质量。由于缺乏治疗创新，围绕这种疾病的治疗进展受到阻碍。据推测，慢性鼻窦炎患者患病鼻窦内血管分布的增加可能有助于通过纳米级脂质体载体改善全身药物输送。这样的系统可以增强药物在鼻窦内的分布、积累和保留，最终改善患者的治疗效果。合成、表征了负载吲哚菁绿 (ICG) 的聚乙二醇化脂质体，并在 CRS 小鼠模型中全身给药。评估了 ICG 在鼻腔组织中的积累和保留。与健康对照相比，CRS 小鼠表现出显着的鼻腔组织积聚和聚乙二醇化脂质体 ICG 的保留长达 21 天（P  < 0.001）。相反，两组中的游离 ICG 均在 24 小时后从体内排出。